GSA Capital Partners LLP Takes Position in Bionano Genomics, Inc. (NASDAQ:BNGO)

GSA Capital Partners LLP bought a new position in shares of Bionano Genomics, Inc. (NASDAQ:BNGO) in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 100,414 shares of the company’s stock, valued at approximately $46,000.

A number of other institutional investors and hedge funds have also recently bought and sold shares of BNGO. Carret Asset Management LLC grew its stake in Bionano Genomics by 89.0% during the third quarter. Carret Asset Management LLC now owns 85,055 shares of the company’s stock worth $39,000 after buying an additional 40,055 shares during the period. Armistice Capital LLC purchased a new stake in Bionano Genomics during the 2nd quarter worth $1,138,000. Cetera Advisors LLC acquired a new stake in Bionano Genomics in the 1st quarter valued at $163,000. Virtu Financial LLC purchased a new position in Bionano Genomics in the first quarter valued at about $36,000. Finally, Price T Rowe Associates Inc. MD lifted its stake in shares of Bionano Genomics by 123.6% during the first quarter. Price T Rowe Associates Inc. MD now owns 70,370 shares of the company’s stock worth $79,000 after purchasing an additional 38,900 shares in the last quarter. Institutional investors and hedge funds own 11.35% of the company’s stock.

Analyst Ratings Changes

A number of research firms have recently issued reports on BNGO. BTIG Research lowered Bionano Genomics from a “buy” rating to a “neutral” rating in a research note on Tuesday, September 10th. LADENBURG THALM/SH SH cut shares of Bionano Genomics from a “buy” rating to a “neutral” rating in a research report on Friday, November 15th. Finally, Scotiabank reaffirmed a “sector perform” rating and set a $1.00 price target (down previously from $6.00) on shares of Bionano Genomics in a research note on Wednesday, August 28th.

Bionano Genomics Stock Up 12.2 %

BNGO stock opened at $0.25 on Tuesday. The company has a market capitalization of $25.64 million, a P/E ratio of -0.11 and a beta of 2.37. The firm has a 50 day simple moving average of $0.34 and a 200-day simple moving average of $0.57. The company has a current ratio of 1.43, a quick ratio of 0.99 and a debt-to-equity ratio of 0.07. Bionano Genomics, Inc. has a twelve month low of $0.20 and a twelve month high of $2.27.

Bionano Genomics Profile

Bionano Genomics, Inc provides genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight DNA.